Insight Molecular Diagnostics (IMDX) Net Income towards Common Stockholders (2015 - 2026)
Insight Molecular Diagnostics (IMDX) posted Net Income towards Common Stockholders of -$4.4 million for Q1 2026, up 80.78% sequentially from -$23.0 million in Q4 2025, and up 33.85% YoY from -$3.3 million in Q1 2025.
Insight Molecular Diagnostics (IMDX) Net Income towards Common Stockholders (2015 - 2026) Analysis & Trends
Insight Molecular Diagnostics (IMDX) has 12 years of Net Income towards Common Stockholders data on file, last reported at -$4.4 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 33.85% year-over-year to -$4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$48.0 million (up 17.68% YoY) and the FY2025 annual result came in at -$50.2 million, up 17.57% from the prior year.
- Net Income towards Common Stockholders improved to -$4.4 million in Q1 2026 per IMDX's latest filing, from -$23.0 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $9.1 million in Q4 2022, with the low at -$33.5 million in Q4 2024.
- Average Net Income towards Common Stockholders over 5 years is -$9.6 million, with a median of -$9.3 million recorded in 2024.
- Year-over-year, Net Income towards Common Stockholders surged 125.32% in 2022 and plunged 389545.14% in 2024.
- Insight Molecular Diagnostics' Net Income towards Common Stockholders stood at $9.1 million in 2022, then tumbled by 246.04% to -$13.3 million in 2023, then tumbled by 152.55% to -$33.5 million in 2024, then jumped by 31.5% to -$23.0 million in 2025, then jumped by 80.78% to -$4.4 million in 2026.
- Business Quant data shows IMDX's Net Income towards Common Stockholders at -$4.4 million in Q1 2026, -$23.0 million in Q4 2025, and -$10.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Waters | 31,055.11 Bn | 31,054.65 Bn | 1.11 Bn | -72.00 Mn |
| 2 | Thermo Fisher Scientific | 191.02 Bn | 187.77 Bn | 7.74 Bn | 1.66 Bn |
| 3 | Danaher | 137.16 Bn | 131.47 Bn | 3.59 Bn | 1.03 Bn |
| 4 | Idexx Laboratories | 42.82 Bn | 42.62 Bn | 722.74 Mn | 278.45 Mn |
| 5 | Natera | 39.09 Bn | 37.99 Bn | 696.04 Mn | -85.11 Mn |
| 6 | Agilent Technologies | 37.61 Bn | 35.81 Bn | 990.00 Mn | 339.00 Mn |
| 7 | Iqvia Holdings | 34.23 Bn | 32.25 Bn | 1.36 Bn | 141.00 Mn |
| 8 | Illumina | 28.14 Bn | 26.98 Bn | 721.00 Mn | 134.00 Mn |
| 9 | Mettler Toledo International | 26.40 Bn | 26.33 Bn | 555.82 Mn | 169.45 Mn |
| 10 | Insight Molecular Diagnostics | 196.41 Mn | 167.48 Mn | 15,000.00 | -4.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.41 Mn |
| Dec 31, 2025 | -22.96 Mn |
| Sep 30, 2025 | -10.85 Mn |
| Jun 30, 2025 | -9.74 Mn |
| Mar 31, 2025 | -6.67 Mn |
| Dec 31, 2024 | -33.51 Mn |
| Sep 30, 2024 | -13.49 Mn |
| Jun 30, 2024 | -4.59 Mn |
| Mar 31, 2024 | -9.34 Mn |
| Dec 31, 2023 | -13.27 Mn |
| Sep 30, 2023 | -6.69 Mn |
| Jun 30, 2023 | -8.64 Mn |
| Mar 31, 2023 | 2,397.00 |
| Dec 31, 2022 | 9.09 Mn |
| Sep 30, 2022 | -9.63 Mn |
| Jun 30, 2022 | -8.37 Mn |
| Mar 31, 2022 | -10.29 Mn |
| Dec 31, 2021 | -35.89 Mn |
| Sep 30, 2021 | -13.80 Mn |
| Jun 30, 2021 | -10.49 Mn |